Pfizer Inc. $PFE Shares Sold by Denali Advisors LLC

Denali Advisors LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.0% during the 2nd quarter, Holdings Channel.com reports. The fund owned 31,700 shares of the biopharmaceutical company’s stock after selling 2,400 shares during the period. Denali Advisors LLC’s holdings in Pfizer were worth $768,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. purchased a new position in Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd purchased a new position in Pfizer during the 1st quarter worth approximately $28,000. Harbor Asset Planning Inc. purchased a new position in Pfizer during the 2nd quarter worth approximately $29,000. Finally, Horizon Financial Services LLC purchased a new position in Pfizer during the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.5%

Shares of PFE stock opened at $24.72 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The business’s 50 day moving average is $24.88 and its two-hundred day moving average is $24.13. The company has a market capitalization of $140.52 billion, a P/E ratio of 13.15, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.17.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on PFE shares. Bank of America raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley lowered their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.